KR20050002925A - 위 음식물 수용능 장해 치료약 - Google Patents
위 음식물 수용능 장해 치료약 Download PDFInfo
- Publication number
- KR20050002925A KR20050002925A KR10-2004-7015764A KR20047015764A KR20050002925A KR 20050002925 A KR20050002925 A KR 20050002925A KR 20047015764 A KR20047015764 A KR 20047015764A KR 20050002925 A KR20050002925 A KR 20050002925A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- compound
- acid addition
- addition salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003814 drug Substances 0.000 title claims abstract description 10
- 229940124597 therapeutic agent Drugs 0.000 title claims description 3
- 235000013305 food Nutrition 0.000 title abstract description 14
- 210000002784 stomach Anatomy 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 41
- 230000002496 gastric effect Effects 0.000 claims abstract description 24
- 239000002253 acid Substances 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 125000000335 thiazolyl group Chemical group 0.000 claims abstract description 10
- 125000002541 furyl group Chemical group 0.000 claims abstract description 8
- 230000006735 deficit Effects 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 229940126585 therapeutic drug Drugs 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000005843 halogen group Chemical group 0.000 claims abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 5
- 125000002971 oxazolyl group Chemical group 0.000 claims abstract description 5
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- -1 4,5-dimethoxy-2-hydroxybenzoyl Chemical group 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- TWHZNAUBXFZMCA-UHFFFAOYSA-N Acotiamide Chemical compound C1=C(OC)C(OC)=CC(O)=C1C(=O)NC1=NC(C(=O)NCCN(C(C)C)C(C)C)=CS1 TWHZNAUBXFZMCA-UHFFFAOYSA-N 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 206010061958 Food Intolerance Diseases 0.000 claims description 2
- 125000006202 diisopropylaminoethyl group Chemical group [H]C([H])([H])C([H])(N(C([H])([H])C([H])([H])*)C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 206010000060 Abdominal distension Diseases 0.000 abstract description 5
- 208000024330 bloating Diseases 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 230000002028 premature Effects 0.000 abstract description 4
- 230000003187 abdominal effect Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 11
- 230000009471 action Effects 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000001647 drug administration Methods 0.000 description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000008447 perception Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 2
- 229960005132 cisapride Drugs 0.000 description 2
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- UPUWMQZUXFAUCJ-UHFFFAOYSA-N 2,5-dihydro-1,2-thiazole Chemical compound C1SNC=C1 UPUWMQZUXFAUCJ-UHFFFAOYSA-N 0.000 description 1
- UMEHMORTTSHRSD-UHFFFAOYSA-N 2-[(2-chloro-4,5-dimethoxybenzoyl)amino]-n-[2-[di(propan-2-yl)amino]ethyl]-1,3-thiazole-4-carboxamide Chemical compound C1=C(OC)C(OC)=CC(Cl)=C1C(=O)NC1=NC(C(=O)NCCN(C(C)C)C(C)C)=CS1 UMEHMORTTSHRSD-UHFFFAOYSA-N 0.000 description 1
- RQGAQSHTOLJBCQ-UHFFFAOYSA-N 2-[(3,4-dimethoxybenzoyl)amino]-n-[2-[di(propan-2-yl)amino]ethyl]-1,3-thiazole-4-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=NC(C(=O)NCCN(C(C)C)C(C)C)=CS1 RQGAQSHTOLJBCQ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical class NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000001762 Gastric Dilatation Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 229960004266 acetylcholine chloride Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000002973 anti-dopamine Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- RVZZUQVNJYUUGU-UHFFFAOYSA-N n-[2-[di(propan-2-yl)amino]ethyl]-5-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]furan-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC(O)=C1C(=O)NC1=CC(C(=O)NCCN(C(C)C)C(C)C)=CO1 RVZZUQVNJYUUGU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 239000000387 serotonin 5-HT4 receptor agonist Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001521 two-tailed test Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2002-00104894 | 2002-04-08 | ||
| JP2002104894 | 2002-04-08 | ||
| PCT/JP2003/004445 WO2003084537A1 (en) | 2002-04-08 | 2003-04-08 | Therapeutic agent for food competence disorder in stomach |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117000220A Division KR20110010837A (ko) | 2002-04-08 | 2003-04-08 | 위 음식물 수용능 장해 치료약 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20050002925A true KR20050002925A (ko) | 2005-01-10 |
Family
ID=28786350
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137022604A Expired - Lifetime KR101423284B1 (ko) | 2002-04-08 | 2003-04-08 | 위 음식물 수용능 장해 치료약 |
| KR1020127005319A Ceased KR20120037035A (ko) | 2002-04-08 | 2003-04-08 | 위 음식물 수용능 장해 치료약 |
| KR1020117000220A Ceased KR20110010837A (ko) | 2002-04-08 | 2003-04-08 | 위 음식물 수용능 장해 치료약 |
| KR10-2004-7015764A Ceased KR20050002925A (ko) | 2002-04-08 | 2003-04-08 | 위 음식물 수용능 장해 치료약 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137022604A Expired - Lifetime KR101423284B1 (ko) | 2002-04-08 | 2003-04-08 | 위 음식물 수용능 장해 치료약 |
| KR1020127005319A Ceased KR20120037035A (ko) | 2002-04-08 | 2003-04-08 | 위 음식물 수용능 장해 치료약 |
| KR1020117000220A Ceased KR20110010837A (ko) | 2002-04-08 | 2003-04-08 | 위 음식물 수용능 장해 치료약 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20050176788A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2301540A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5281226B2 (cg-RX-API-DMAC7.html) |
| KR (4) | KR101423284B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN1646123A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE522214T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003236326B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2481916C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1112057T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1493441T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2368732T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1493441E (cg-RX-API-DMAC7.html) |
| SI (1) | SI1493441T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003084537A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104447612A (zh) * | 2013-09-16 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 阿考替胺水合物晶型及其制备方法和用途 |
| CN103980226A (zh) * | 2014-05-10 | 2014-08-13 | 杭州新博思生物医药有限公司 | 盐酸阿考替胺水合物晶型及其制备方法 |
| CN105315225A (zh) * | 2014-07-07 | 2016-02-10 | 中美华世通生物医药科技（武汉）有限公司 | 阿考替胺的酸加成盐及其制备方法 |
| CN104045606B (zh) * | 2014-07-11 | 2015-09-30 | 杭州新博思生物医药有限公司 | 一锅法制备阿考替胺盐酸盐的方法 |
| CN109988121B (zh) * | 2019-04-28 | 2023-01-03 | 梯尔希（南京）药物研发有限公司 | 一种阿考替胺衍生物的制备方法 |
| MX2024000751A (es) | 2021-07-14 | 2024-03-25 | Blueprint Medicines Corp | Compuestos heterociclicos como inhibidores de map4k1. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1063442C (zh) * | 1995-05-18 | 2001-03-21 | 泽里新药工业株式会社 | 氨基噻唑衍生物、含有它们的药物组合物及其用途 |
| JPH10212271A (ja) * | 1997-01-31 | 1998-08-11 | Zeria Pharmaceut Co Ltd | Ｎ−置換ベンゾイルアミン誘導体、それを含有する医薬及び該化合物の製造中間体 |
| PT994108E (pt) * | 1997-06-24 | 2003-09-30 | Zeria Pharm Co Ltd | Processo de producao de derivados de 2-hidroxibenzamida |
| US5981556A (en) * | 1997-07-22 | 1999-11-09 | G.D. Searle & Co. | 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors |
| NZ511117A (en) * | 1998-11-23 | 2002-11-26 | Janssen Pharmaceutica Nv | Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia |
| JP2003501427A (ja) * | 1999-06-02 | 2003-01-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | アミノアルキル置換（ベンゾジオキサン、ベンゾフランもしくはベンゾピラン）誘導体 |
| CA2391497C (en) * | 1999-11-23 | 2008-12-30 | Janssen Pharmaceutica N.V. | Use of 5ht3 agonists for relaxing the fundus |
| GB0002336D0 (en) * | 2000-02-01 | 2000-03-22 | Glaxo Group Ltd | Medicaments |
| JP4876367B2 (ja) * | 2000-09-08 | 2012-02-15 | ゼリア新薬工業株式会社 | アミノチアゾール誘導体を有効成分とする大腸運動不全治療剤 |
| US6986882B2 (en) * | 2002-01-17 | 2006-01-17 | Astrazeneca Ab | Therapy for functional dyspepsia |
-
2003
- 2003-04-08 CN CNA038079755A patent/CN1646123A/zh active Pending
- 2003-04-08 SI SI200332073T patent/SI1493441T1/sl unknown
- 2003-04-08 AU AU2003236326A patent/AU2003236326B2/en not_active Expired
- 2003-04-08 PT PT03745958T patent/PT1493441E/pt unknown
- 2003-04-08 CN CN201010611741.5A patent/CN102125551B/zh not_active Expired - Lifetime
- 2003-04-08 KR KR1020137022604A patent/KR101423284B1/ko not_active Expired - Lifetime
- 2003-04-08 JP JP2003581777A patent/JP5281226B2/ja not_active Expired - Lifetime
- 2003-04-08 WO PCT/JP2003/004445 patent/WO2003084537A1/ja not_active Ceased
- 2003-04-08 US US10/509,335 patent/US20050176788A1/en not_active Abandoned
- 2003-04-08 KR KR1020127005319A patent/KR20120037035A/ko not_active Ceased
- 2003-04-08 EP EP10010621A patent/EP2301540A1/en not_active Withdrawn
- 2003-04-08 DK DK03745958.3T patent/DK1493441T3/da active
- 2003-04-08 EP EP03745958A patent/EP1493441B1/en not_active Expired - Lifetime
- 2003-04-08 ES ES03745958T patent/ES2368732T3/es not_active Expired - Lifetime
- 2003-04-08 KR KR1020117000220A patent/KR20110010837A/ko not_active Ceased
- 2003-04-08 CA CA2481916A patent/CA2481916C/en not_active Expired - Lifetime
- 2003-04-08 KR KR10-2004-7015764A patent/KR20050002925A/ko not_active Ceased
- 2003-04-08 AT AT03745958T patent/ATE522214T1/de active
-
2009
- 2009-02-17 US US12/372,234 patent/US20090156652A1/en not_active Abandoned
-
2011
- 2011-01-05 JP JP2011000499A patent/JP5360075B2/ja not_active Expired - Lifetime
- 2011-11-16 CY CY20111101103T patent/CY1112057T1/el unknown
-
2014
- 2014-12-22 US US14/579,102 patent/US20150141475A1/en not_active Abandoned
-
2020
- 2020-08-20 US US16/998,637 patent/US20200375954A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120037035A (ko) | 2012-04-18 |
| KR101423284B1 (ko) | 2014-07-24 |
| AU2003236326B2 (en) | 2008-02-28 |
| ES2368732T3 (es) | 2011-11-21 |
| JP5281226B2 (ja) | 2013-09-04 |
| PT1493441E (pt) | 2011-09-28 |
| EP1493441B1 (en) | 2011-08-31 |
| JP2011068692A (ja) | 2011-04-07 |
| CA2481916C (en) | 2013-02-26 |
| EP1493441A1 (en) | 2005-01-05 |
| DK1493441T3 (da) | 2011-10-17 |
| JPWO2003084537A1 (ja) | 2005-08-11 |
| US20090156652A1 (en) | 2009-06-18 |
| KR20130101162A (ko) | 2013-09-12 |
| CY1112057T1 (el) | 2015-11-04 |
| EP1493441A4 (en) | 2007-10-17 |
| ATE522214T1 (de) | 2011-09-15 |
| US20200375954A1 (en) | 2020-12-03 |
| KR20110010837A (ko) | 2011-02-07 |
| JP5360075B2 (ja) | 2013-12-04 |
| WO2003084537A1 (en) | 2003-10-16 |
| US20150141475A1 (en) | 2015-05-21 |
| CA2481916A1 (en) | 2003-10-16 |
| EP2301540A1 (en) | 2011-03-30 |
| CN1646123A (zh) | 2005-07-27 |
| AU2003236326A1 (en) | 2003-10-20 |
| SI1493441T1 (sl) | 2011-12-30 |
| CN102125551B (zh) | 2015-07-22 |
| CN102125551A (zh) | 2011-07-20 |
| US20050176788A1 (en) | 2005-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200375954A1 (en) | Therapeutic agent for food competence disorder in stomach | |
| KR101639821B1 (ko) | 염증성 장질환 치료제 | |
| JP2006528198A (ja) | 酸不安定な医薬組成物の即時放出製剤 | |
| DK2900230T3 (en) | RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF | |
| RU2672248C1 (ru) | Применение производного бензимидазола для лечения ночного кислотного прорыва | |
| AU2013237881B2 (en) | Dosage forms of halofuginone and methods of use | |
| JP3872834B2 (ja) | メイラード反応抑制剤 | |
| JP4876367B2 (ja) | アミノチアゾール誘導体を有効成分とする大腸運動不全治療剤 | |
| EP1300155A1 (en) | Enteric preparations containing physiologically active peptides | |
| HUT63055A (en) | Process for producing pharmaceutical compositions for relieving diuria | |
| JP2006076956A (ja) | 胃炎の治療・予防用配合剤 | |
| JP2021172639A (ja) | 医薬組成物 | |
| WO2016047662A1 (ja) | 脳卒中の治療剤 | |
| KR20170000907A (ko) | 애엽의 이소프로판올 추출물을 포함하는 약제학적 조성물 | |
| WO2008026668A1 (en) | Medicinal composition containing insulin resistance improving agent | |
| JP2000290198A (ja) | 鼻腔抵抗上昇等の抑制剤 | |
| KR20170001668A (ko) | 애엽의 이소프로판올 추출물을 포함하는 약제학적 조성물 | |
| HK1106701A (en) | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease | |
| JP2002205939A (ja) | 抗潰瘍剤組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20041004 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20080402 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20100127 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20100907 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20100127 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20101207 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20100907 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20110609 Appeal identifier: 2010101009417 Request date: 20101207 |
|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20110105 |
|
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20101207 Effective date: 20110609 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20110609 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20101207 Decision date: 20110609 Appeal identifier: 2010101009417 |